JPWO2021225011A1 - - Google Patents

Info

Publication number
JPWO2021225011A1
JPWO2021225011A1 JP2020562225A JP2020562225A JPWO2021225011A1 JP WO2021225011 A1 JPWO2021225011 A1 JP WO2021225011A1 JP 2020562225 A JP2020562225 A JP 2020562225A JP 2020562225 A JP2020562225 A JP 2020562225A JP WO2021225011 A1 JPWO2021225011 A1 JP WO2021225011A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020562225A
Other versions
JP6810502B1 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2020/018731 external-priority patent/WO2021224999A1/ja
Application filed filed Critical
Application granted granted Critical
Publication of JP6810502B1 publication Critical patent/JP6810502B1/ja
Publication of JPWO2021225011A1 publication Critical patent/JPWO2021225011A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020562225A 2020-05-08 2020-09-11 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 Active JP6810502B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2020/018731 WO2021224999A1 (ja) 2020-05-08 2020-05-08 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
JPPCT/JP2020/018731 2020-05-08
PCT/JP2020/034524 WO2021225011A1 (ja) 2020-05-08 2020-09-11 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤

Publications (2)

Publication Number Publication Date
JP6810502B1 JP6810502B1 (ja) 2021-01-06
JPWO2021225011A1 true JPWO2021225011A1 (ja) 2021-11-11

Family

ID=73993042

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562225A Active JP6810502B1 (ja) 2020-05-08 2020-09-11 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
JP2021034353A Pending JP2021176833A (ja) 2020-05-08 2021-03-04 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021034353A Pending JP2021176833A (ja) 2020-05-08 2021-03-04 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤

Country Status (4)

Country Link
US (2) US11285109B2 (ja)
JP (2) JP6810502B1 (ja)
KR (1) KR20220163416A (ja)
CN (1) CN115551485A (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220151622A (ko) 2020-02-06 2022-11-15 오큘라 테라퓨틱스, 인코포레이티드 안질환 치료를 위한 조성물 및 방법
JP6792900B1 (ja) * 2020-05-08 2020-12-02 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
WO2022168540A1 (ja) 2021-02-08 2022-08-11 株式会社デンソー 表示制御装置及び表示制御プログラム
WO2023170962A1 (ja) * 2022-03-11 2023-09-14 エム・テクニック株式会社 噴霧乾燥機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
KR100321854B1 (ko) 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
JP4547995B2 (ja) 2003-06-03 2010-09-22 参天製薬株式会社 微粒子の製造法
KR100466637B1 (ko) 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
PT1968549E (pt) 2005-12-22 2014-08-29 Novartis Ag Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US10632079B2 (en) 2007-06-25 2020-04-28 Otsuka Pharmaceuticals Co., Ltd. Microspheres having core/shell structure
JP4856752B2 (ja) 2009-11-30 2012-01-18 ホソカワミクロン株式会社 薬物含有ナノ粒子の製造方法
CN103054809A (zh) * 2011-12-22 2013-04-24 苏州雷纳药物研发有限公司 一种包含姜黄素微粒的高载药量缓释微球及其制备方法和用途
KR101543507B1 (ko) 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
JP6238401B2 (ja) * 2013-10-28 2017-11-29 日本化薬株式会社 生理活性ペプチド徐放性微粒子及びその製造方法
CN114191538A (zh) 2014-03-31 2022-03-18 法尔玛赞公司 具有控释特征的装载肽的plga微球体的制备
US10449152B2 (en) 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain

Also Published As

Publication number Publication date
US20210346297A1 (en) 2021-11-11
US11285109B2 (en) 2022-03-29
JP6810502B1 (ja) 2021-01-06
KR20220163416A (ko) 2022-12-09
JP2021176833A (ja) 2021-11-11
CN115551485A (zh) 2022-12-30
US20220168224A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
BR112023005462A2 (ja)
BR112023012656A2 (ja)
BR112021014123A2 (ja)
BR112022024743A2 (ja)
BR102021018859A2 (ja)
BR102021015500A2 (ja)
BR112022009896A2 (ja)
BR102021007058A2 (ja)
BR102020022030A2 (ja)
BR112023011738A2 (ja)
BR112023016292A2 (ja)
BR112023004146A2 (ja)
BR112023011539A2 (ja)
BR112023011610A2 (ja)
BR112023008976A2 (ja)
BR112023009656A2 (ja)
BR112023006729A2 (ja)
BR102021020147A2 (ja)
BR102021018926A2 (ja)
BR102021018167A2 (ja)
BR102021017576A2 (ja)
BR102021016837A2 (ja)
BR102021016551A2 (ja)
BR102021016375A2 (ja)
BR102021016176A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201105

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20201105

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201204

R150 Certificate of patent or registration of utility model

Ref document number: 6810502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250